Maximus Inc

NYSE:MMS

Earnings Call Transcript 2023-Q1

[Operator]

Greetings, and welcome to the Maximus Fiscal 2023 First Quarter Earnings Conference Call. At this time, all participants are in a listen-only. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Jessica Batt, Vice President of Investor Relations and ESG for Maximus. Thank you. Ms. Batt. You may begin.

[Jessica Batt]

Good morning and thanks for joining us. With me today is Bruce Caswell, President and CEO; David Mutryn, CFO; and James Francis, Vice President of Investor Relations.

I'd like to remind everyone that a number of statements being made today will be forward-looking in nature. Please remember that such statements are only predictions. Actual events and results may differ materially as a result of the risks we face, including those discussed in Item 1A of our most recent Forms 10-Q and 10-K.

We encourage you to review the information contained in our most recent filings with the SEC and our earnings press release. The company does not assume any obligation to revise or update these forward-looking statements to reflect subsequent events or circumstances, except as required by law.

Today's presentation also contains non-GAAP financial information. Management uses this information internally to analyze results and believes it may be informative to investors in gauging the quality of our financial performance, identifying trends, and providing meaningful period-to-period comparisons. For a reconciliation of the non-GAAP measures presented, please see the company's most recent Forms 10-Q and 10-K.

And with that, I'll hand the call over to David.

[David Mutryn, Chief Financial Officer]

Thanks, Jessica, and good morning. We are pleased to report solid first quarter results, as well as increased our revenue and earnings guidance for fiscal 2023. We have some important updates to share regarding Medicaid redeterminations that are now scheduled to commence later this fiscal year.

First, I will discuss results for the quarter. Maximus reported revenue of $1.25 billion for the first quarter of fiscal year 2023, which represents 8.5% year over year growth. Organic growth was 10.3%, driven by new or expanded programs in all three segments. As we continue to see strong demand for our services across our markets.

Adjusted operating income margin was 7.9% and adjusted EPS was $0.94 for the quarter. This compares to 9.0% and $1.12 respectively, for the prior year period, which included profitable short-term COVID response work in the domestic segments and less interest expense due to lower interest rates.

Let's go to segment results. For the US federal services segment, revenue increased 6.2%, to $618 million, driven primarily by volume growth, tied to strong demand in the segments clinical services business and anticipated higher revenue on a large cost plus contract.

The operating income margin for U.S. Federal Services in the first quarter was 8.3% as compared to 10.6% in the prior year period. Segment income results were in line with our expectation for a lighter quarter and our expectations for the full year are unchanged.

For the U.S. services segment revenue increased 13.7% to $439 million. This was driven by contributions from new work wins across the portfolio in core business areas such as eligibility support, and clinical services that we have discussed on recent quarterly calls.

The U.S. services operating income margin was 8.6% in the first quarter of fiscal 2023 reflecting the ongoing headwind to the segment's profitability caused by paused Medicaid redetermination activities. Now that we have clarity on restarting redeterminations, which has factored into our updated guidance, we expect improvement to operating margin for this segment.

Turning to outside the U.S. segment. Revenue increased 5% year-over-year to $192 million for the quarter. This is net of currency impacts, which have been meaningful in the past year and reduce revenue by approximately 12% from the prior year period.

Organic growth, which excludes the currency impact was 16.0% and driven primarily by volume increases on the U.K. restart program that has now reached its full run rate. Operating income margin for outside the U.S. in the first quarter was 5.3%.

The segment had an operating loss in the prior year period due to contracts with planned startup losses, such as the U.K. restart program. Today that contract is performing to expectations, meaning, it is more than overcoming the planned startup loss and helping to drive overall profitability in the segment.

Let's turn to the balance sheet and cash flow items, starting with cash flows. For the quarter ended December 31, 2022 cash used in operating activities totaled $135 million, and free cash flow was an outflow of $150 million. We had anticipated lower cash flows for this quarter, due to the timing of certain payments, like the final payment of payroll taxes that were deferred from 2020 and seasonality around collections given the holidays.

Collections in December were lighter than expected, which brought DSOs at the end of the quarter to 74 days, above the range we typically expect of 60 days to 70 days, we expect the increase to be temporary, with DSOs quickly falling back into our targeted range.

In the December quarter, we borrowed on our revolver to support the higher working capital, already in the month of January, we've used improved cash collections to pay it back down by $75 million. As a result of the lower collections, we finished the December quarter with total debt of $1.57 billion and our net debt to EBITDA ratio at approximately three times, putting it at the upper end of our target range of two times to three times. As a reminder, this ratio is our debt net allowed cash to adjusted EBITDA for the last 12 months, as calculated in accordance with our credit agreement.

Looking forward, we expect our debt ratio to improve over the remainder of fiscal year 2023. I view December as a high watermark given the temporarily higher DSO. Over the next three quarters, our cash flow is consistent with our guidance range should enable us to finish the fiscal year below 2.5 times. Our capital allocation strategy remains unchanged from last quarter.

In the near term, we plan to prioritize debt reduction using our free cash flow. Longer-term, our core focus remains strategic acquisitions intended to accelerate organic growth.

Turning to fiscal year 2023 guidance. The Consolidated Appropriations Act, 2023 also known as the omnibus spending bill was passed in late December and included direction to states on resuming Medicaid redeterminations and the associated funding. Bruce will provide further remarks on the specifics of the policy and related schedule that states are targeting. But we now have a high degree of certainty that the redetermination work will commence during our third fiscal quarter.

As a result, we are increasing our outlook for fiscal 2023 to reflect redeterminations volumes, which were not previously assumed and guidance. Working up from the bottom, our fiscal 2023 guidance is increased as follows. Adjusted EPS excluding intangibles amortization is now projected to be between $4 and $4.30 per share. This reflects a $0.30 raise from prior guidance.

Adjusted operating income is estimated to be between $415 million and $440 million, which is before the estimated $94 million of intangibles amortization expense. Revenue is now projected to be between $4.85 billion and $5 billion. This represents year-over-year growth of 5% to 8% substantially all organic and overcomes the $300 million reduction in short-term COVID response work. This reflects an increase of $100 million from our prior guidance.

We are maintaining free cash flow guidance of $225 million to $275 million for fiscal 2023.

While our profit forecast is up, we are factoring in some working capital increase in the fourth quarter, as a result of higher revenue. You may note, that the redetermination benefit we have assumed in the second half of the year suggests the lower end of our previously communicated range of $0.15 to $0.30 per quarter. There are a few things at play.

First, as we've indicated previously, states are in varying degrees of readiness. Even those who have been deliberate in their planning for the unwinding, we see taking extra time to coordinate all aspects of their operations and systems. In short, we currently expect the redetermination volumes for us phasing and during our third quarter, and we forecast more of a full quarter contribute addition in the fourth quarter.

Second, it still remains to be seen exactly how the volumes tied to redetermination activities will flow through our programs, which can have an impact on profitability, and was one of a few reasons why we previously provided a wide-range on the per quarter benefit. As a reminder, the impact to us is a function of each contracts specific pay points, as well as how beneficiaries ultimately interact with the process.

And third, their states with whom we are in active dialogue, to potentially help them approach the unwinding tasks, now that there's clarity around the timeline. Our fiscal 2023 guidance assumes volumes for which we have a strong line of sight on our core programs, additional scope or volume with new or existing customers could represent further upside.

As a final thought, I'd like to remind investors, that redeterminations are a normal annually recurring component of Medicaid programs, which we support with many state customers. While the resumption of redeterminations after a pause of three years will likely create a surge of activity, we would expect the volume impact to our core programs to continue on, as it did before-COVID.

Turning to segment margins, we still expect U.S. federal services in the 10% to 11% range. U.S. services should finish stronger in the back half of the year due to the redeterminations. And the full year blended expectation is now nine to 11% and increase from our previous range of eight to 10%. We still expect outside the U.S. operating income margins near the low-end of the three to 7% target range.

We are refining our interest expense projection, and reducing the top end of the range by $5 million. We now expect between $85 million and $90 million of interest expense. We expect a full year effective income tax rate between 24.5% and 25.5% and weighted average shares outstanding between $61.2 million and $61.3 million.

With that, I will turn the call over to Bruce.

[Bruce Caswell, President & Chief Executive Officer]

Thank you, David, and good morning everyone. As David noted, a significant developments since our last call is the establishment of requirements and a specific timeline that states must follow for restarting annual redetermination of Medicaid eligibility.

As a result, a number of our core programs, which have been operating with reduced volumes since the pandemic began are preparing for this major undertaking. In addition, demand in the broader Medicaid market has increased as all states must evaluate their entire populations for eligibility with only a few exceptions permitted.

A brief background, signed into law by President Biden on December 29, 2022, the Consolidated Appropriations Act of 2023, also known as the Omnibus Spending Bill ends the temporary Medicaid continuous enrollment requirements of the families first coronavirus response act by decoupling it from the public health emergency or PHE, while also providing clear guidance on start and end dates for the unwinding process.

While it was announced last week that the PHE is scheduled to end on May 11th of this year, the rules provided in the spending bill around redeterminations effectively superseded any reliance on the timing of the PHE.

In terms of key unwinding dates. States were permitted to initiate the redetermination process as early as last week on February 1st, and must start by April of this year. With respect to this process, initiate means attempting to renew eligibility using pre-existing information on hand, including third-party data sources without contacting the individual.

If a definitive determination of eligibility cannot be made, states will then notify beneficiaries who need to submit updated information in order to remain enrolled. These enrollments can be effective as early as April 1st, provided adequate notice is given to the enrollee. And then states must complete all renewals within 14 months from the beginning of the state's unwind period, which as I mentioned, cannot start later than this April.

All of this means that redetermination work can begin as early as last week and end 16 months from now. As we've said in the past, we expect this work to stretch into the next fiscal year. CMS is encouraging states to distribute renewals in a reasonable manner and suggests processing no more than one-ninth of their total renewals in a given month.

The enhanced federal funding known as the Federal Medical Assistance Percentage or FMAP, which has been at 6.2%, tapers down in sunsets at December 31, 2023. This further incentivizes states to approach the unwinding in a level loaded manner.

We anticipate some states with larger populations, which include our current customers processing 112 each month, spreading the work over a full year and following, in most cases, their historical level loaded model for annual renewals. That means, including the initiation periods, there's more than a year in which Maximus will be supporting our state customers in working through this renewal workload.

We see States taking advantage of the short runway they have now to get ready, which is why we anticipate seeing an uptick in volumes during our third fiscal quarter and achieving run rate levels in the fourth quarter, as David noted. In preparation for redeterminations, Maximus teams have been working with current and prospective clients to inform their plans and tailor our services to varying approaches and timelines.

Our delivery model can accommodate these varied approaches, and we've been fortunate to be able to offer continued employment opportunities to hundreds of staff who were ramping down from open enrollment. The ability to scale staff and IT quickly gained during the pandemic, is paying dividends, as we approach this unprecedented period with our Medicaid customers. Meanwhile, we continue to deliver on the three to five year strategy outlined at our investor day last May and supported by the long-term growth drivers in our markets.

I'll take the next few minutes to highlight a few of our recent successes, aligned with our three areas of focus, future of health, advanced technologies for modernization, and customer services digitally enabled. Aligned with our future of health focus, within our US services segment, we recently won a new clinical work with a long standing state customer. Our team of clinicians will be carrying out a variety of complex health assessments, including level of care, and Preadmission Screening and Resident Review or PASRR assessments.

On behalf of the State agency, as well as providing helpline assistance and Medicaid LTSS application support, this win with a total contract value or TCV of $129 million over a four year base period, demonstrates our ability to successfully expand into adjacent service areas with longtime customers, as program policy and needs evolve.

I would also like to share some exciting news at the federal level in our strategic focus area of technology modernization. As was reported on January 6 by Washington technology, Maximus was selected as one of two organizations to support the Enterprise Development Operations Services or EDOS contract vehicle for the IRS is information technology Application Development Office.

The scope delivered via successive task orders includes IT services across a broad range of categories and functions to assist the agency in systems engineering and enterprise architecture, defect reporting and tracking, configuration management, and IT systems Programming and Source Code Development. This award for a position on the contract vehicle further demonstrates our deep understanding of the IRSs current challenges and capability to support their future modernization journey with a ceiling of $2.6 billion over seven years. This is a strategic win for Maximus.

As was also reported, this award is currently under protest and the resolution is expected by mid-April. Given this uncertainty, we are not assuming any contributions in FY 2023 and look forward to providing updates as the procurement process moves toward completion.

In our OUS segment, we recently were awarded a new contract in the Gulf region. The contract has a five year base period worth $215 million. This win is continued evidence of our unmatched ability to translate public policy into operating models that achieve outcomes for governments at scale. Working with the client and local charities, our team will be tasked with performing annual surveys of approximately 0.5 million social welfare beneficiary households to ensure new eligibility rules are consistently applied. So those with the greatest need are cared for. Expanding our services into an adjacent program domain, the award also evidences the trust our customers have built with Maximus over more than a decade in the region.

Turning to our VES business, as mentioned on prior calls, the PACT Act volumes were anticipated to materialize in early calendar year 2023. We're pleased to report that our team members are starting to see this volume come to fruition. The PACT Act expands certain conditions under which veterans would presumptively qualify for benefits and therefore result in increases in Medical Disability Exam or MDE volumes.

Due to the additional benefit, the increased volumes from the PACT Act are anticipated to be sustained well into FY 2024 as we work through initial claims. While it is still early, it's logical to assume that volumes will settle to a higher level than present over the longer term. I'm proud of the team that's stepping up in even greater service to our nation's veterans.

With respect to Aidvantage, our student loan servicing program, at the time of our Q4 earnings call returned to repayment was expected to commence January 1. Since then, due to ongoing litigation regarding President Biden's Debt Relief Program, the Department of Education Federal Student Aid Office, or FSA, has pushed the end of deferrals to the earlier of 60 days after the litigation is resolved, or 60 days after June 30 2023. These prospective outcomes are contemplated in the updated guidance that we've laid out today.

As the FSA looks toward return to repayment later this fiscal year, we remain committed to their stated goals of improving the borrower experience through improved performance, transparency and accountability under the loan servicing contract. Understanding that 2023 budget constraints exist within Department of Education, our plans to implement best practices in continuous review, performance management, and quality monitoring to promote greater transparency and maintain compliance remain.

I'll now turn to award metrics and pipeline as of December 31st. For the first quarter of fiscal 2023, signed awards totaled $480.9 million of TCV. Further, at December 31st, there were $661.1 million worth of contracts that had been awarded, but not yet signed. These awards translate into a book-to-bill of approximately 2.2 times for the trailing 12-month period.

Let's turn our attention to our pipeline of opportunities. Our pipeline at December 31st was $30.5 billion, compared to $30.7 billion reported in the fourth quarter of fiscal 2022. The December 31st pipeline is comprised of approximately $6 billion in proposals pending, $1.7 billion in proposals in preparation, and $22.8 billion in opportunities tracking.

Of our total pipeline of sales opportunities, 74% represents new work. Additionally, 56% of the 30.5 billion total pipeline, is attributable to our US Federal services segment. On our last call, I noted that we’re fortunately entering FY 2023 with momentum, as evidenced by a record backlog, a healthy pipeline, strong core business delivery, minimal near-term rebid risk and solid progress delivering the business in a tough interest rate environment.

Nothing in that regard has changed. But notably, we now find ourselves with improved visibility with respect to Medicaid redeterminations and evidence of pack stack volumes ramping areas that previously presented the greatest forward looking uncertainty.

While David and I have been clearly note that the nationwide redetermination of more than 90 million individuals on Medicaid and CHIP is unprecedented in its scope. And states have significant discretion as to their approach. We also underscore our view that this work is very different from the short-term work we took on during the pandemic.

The level loading of volumes into the next fiscal year, as well as the requirement to recheck eligibility annually, provides longer range visibility than we have had in some time. It's one thing to see our organization embrace our three to five year strategic plan, as I also noted last quarter, and another for to gain traction in the market.

I'm pleased with the green shoots we've seen this quarter in the areas of clinical assessments and technology modernization and the directional affirmation they provide. Maximus is well positioned in addressable markets comprising $150 billion in annual government spending, and continues to benefit from favorable long-term growth drivers.

During periods of fiscal and budgetary uncertainty, our under exposure to discretionary spending, compared to the broader gulf con community is in our view beneficial, as we continue into this period of greater stability. Scale is again building in the business. And with it, we're executing on our plans to structure the company optimally for the future, and deliver on margin expectations.

Finally, I'd like to thank the more than 10,000 Maximus employees for their contributions to a very successful open enrollment season for our customers and in advance for their upcoming work on Medicaid Redeterminations. Across the company, as we did during the pandemic. We take great pride in being of service in support of some of the most critical government programs here and abroad.

And With that, we'll open the line for Q&A. Operator?

[Operator]

Thank you. We will now be conducting a question-and-answer session. Now, I will now turn it over to James Francis, Investor Relations.

[James Francis, Vice President of Investor Relations]

Thank you. Let's first go to the line of Charlie Strauzer with CJS Securities. Good morning, Charlie.

[Charlie Strauzer, CJS Securities]

Good morning, James. How are you?

[James Francis, Vice President of Investor Relations]

Great. Thank you. We got Bruce and David here.

[Bruce Caswell, President & Chief Executive Officer]

Hi, Charlie. Good morning.

[Charlie Strauzer, CJS Securities]

Good morning. A few questions on the redetermination restart here. As you think about the short term spike that you mentioned, how much of that is kind of incremental redetermination work and you can give us some additional context around that?

[Bruce Caswell, President & Chief Executive Officer]

Happy to, and I'll begin and then ask David to add his thoughts as well. So interestingly, part of our core work for our Medicaid customers, as we've been saying it's performed these redeterminations. In historically they're done on an annual basis for the population that we serve.

During the pandemic, the states halted those, as we've talked about, and in many just didn't take any action whatsoever. But it's important to note some States continued their redetermination process, but just didn't take any case actions. So in some cases, there are states that have more recent and fresh information on the population than others.

As I mentioned, during my prepared remarks, states will begin the process by using third party data sources, or what the government calls ex-parte data sources, which allows them to make really the most least invasive, if you will determination of re-eligibility for the program. And if that data is insufficient then they have a period where they notice individuals and try to collect fresh information.

So that's a little bit on the mechanics, the population. When we began the pandemic, we were at about 71 million Medicaid and CHIP beneficiaries that's gone up by about 20 million. There's a good Urban Institute report that talks about this, and Kaiser has always been has been released aid and CMS as well. So 91 million is kind of the conventional wisdom of the current total enrollment which may have increased a little bit in since that was reported in October of last year.

So with those many adults that need to be redetermined for eligibility, there's a 14 month period, we anticipate there being a high watermark, as you've noted, in that the reason for that is, first of all, while there will generally be level loading, there are states that are going to want to get through the process more expeditiously. Some states, in fact, even have mandates in place from their legislatures to move quickly through this. Similarly, the federal funding will end that's been enhanced that 6.2% of the federal match will end in December. So, we anticipate some states moving relatively quickly through that.

However, as we look at it for the populations that we serve, we believe that these redeterminations will continue on through Q3 of fiscal year 2024. And then I'll add a couple of quick -- I'd say environmental caveats to this, and then turn it over to David for the actual number of where we think will land. There is obviously a high correlation between Medicaid enrollments and unemployment. So it's possible, depending on what the economic conditions are, as we move through the next year, that you could see enrollment stabilizing at a higher level, than we saw a pre pandemic, if the economy were to soften.

Another point is that, one of the trades that was made in order to decouple redeterminations from the public health emergency was to provide enhanced eligibility and extended eligibility for certain populations, like postpartum women. And for children's, there are some states, in fact, like Oregon, now that basically have kids on shift, I think for six years without any redeterminations. So that could also contribute to higher, a higher final, if you will, water level.

And then the last point I would make is that, I see this not dissimilar to the pandemic when we went out and work with 17 different state labor departments to provide unemployment insurance support. So, while by our calculations, there's about 39%, of the Medicaid population that is not currently in states that use vendors to support eligibility support, and therefore redeterminations. These are customers that, if they find themselves in a pinch, that we can develop relationships with and add, if you will, new state customers through this process, not dissimilar to what we did during the pandemic. So that could also affect the final number, but David is going to put a number on it.

[David Mutryn, Chief Financial Officer]

Thanks, Bruce. Yeah, I can say that at least $0.15 per quarter is a reasonable floor for our expected earnings contribution after the unwinding phase. I do have to caution that it's difficult to be precise here, given that we haven't begun the work yet and experienced the actual volume flows. And also, point out that if we experienced volumes that bring us towards the high end of that $0.15 to $0.30 range or even beyond, there's more likely to be a component there that's temporary surge in nature that may decline after the 12 to 14 months.

And then last point is just a reminder, these are not typically separate pay points in our contracts, they really just drive volumes of interaction that have until 2020 always been a part of our contracts that we consider in our pricing structure. So, this specific item is not something we'll be able to continuously quantify, but we've done our best here to estimate and disclose the impact of our core programs returning to a more normal level of volume.

[Charlie Strauzer, CJS Securities]

Great, that's very helpful. Both you thank you very much for that. And then just turning to more on the margin side, do you need to ramp hiring to support the restart? And then follow-on to that would be what is kind of the state of wage inflation that you're experiencing -- that you have been experiencing prior and your ability to attract qualified candidates?

[David Mutryn, Chief Financial Officer]

Sure thing. Starting with the margin. So, yes, there is some cost ramp up, which plays into our Q3 having a partial benefit and Q4 and more of a full run rate as we talked about. But we still do believe that this volume will be highly accretive, as we've been saying for many quarters now. And that really relates to the fact that the pricing structure is where many of our contracts is contemplated this level of volume, which has been missing for three years now.

But stepping back with some margin commentary, the FY 2023 guidance implies an adjusted OI margin of 8.6% to 8.8%, which is a function of fiscal year 2023 having a partial period where we do not have the redetermination from the first half.

Last May at Investor Day, we set adjusted OI margin range of 9% to 12% once redeterminations begin. Our forecast for Q4, which has the full period contribution does have a falling within that target range.

And as we committed at the May Investor Day, we intend to improve our margins over time. One component of which is continuously refining our cost structure and carefully managing our costs as we grow. We've been giving that even more attention recently, as I noted last quarter. And I should also mention that our strategy is to grow a higher mix of clinical and technology work, which we think can drive higher margins over time as well.

[Bruce Caswell, President & Chief Executive Officer]

And I'll jump in and give David a break and talk a little bit about the labor market and ask him to add anything he'd like. I've really been pleased, Charlie to see how the market has improved, since we really last had the opportunity to report on it. And we've seen some positive trends related to voluntary attrition rates that are declining across our business, really across all three segments.

And we're pleased, for example, even outside the US where we're able to attract and retain clinicians on our flagship [Indiscernible] contract in the United Kingdom and get closer to the overall staffing levels that we've been seeking to achieve there.

Furthermore, of course, there's been a real trend, as you're well aware in the tech industry, toward at least the temporary layoffs across a number of the major tech services companies. And I think the Gov Con community has really been benefiting from that we offer opportunities for stable employment and productive mission oriented work for a lot of individuals. And I think they're taking advantage of that.

If you couple that with in many instances, the ability to work remotely, we found that to be a very attractive arrangement for candidates. So we -- one of the metrics we always look at is how many positions do we have in our technology services business that you -- but for having a candidate could be built out tomorrow. And that number has been steadily declining. In fact, just this week, we held a tech fair, a tech hiring fair here at our headquarters in Tysons which was very, very well attended. And there was quite a buzz in the building that day. So I'm feeling really good about that.

The other comment I would add is that our customers are certainly understanding of the wage pressures that we've faced, and I said on a prior call, that we would not hesitate to go to customers well in advance of rebids of our contracts to discuss adjustments to accommodate rising wages in the marketplace. And we have done just that. And, and we've been met with I will say, more sympathetic and understanding, environment than I might have previously anticipated. So we've been able to make some progress in there in that area.

And then lastly, as the portfolio gets rebid, right, that's the natural opportunity to reset and we level prices in the market. And we've continued to win and grow organically in that environment, which I think it's a good illustration of the market rates being higher than they were a few years ago. One of the things we've said around here is, you know, the $13 is now $18 in many cases, right, in some of these contracts, or more, and that's evidence that the market can bear those higher rates. So that's, that's our view on labor. I think the conditions have generally been improving.

[Charlie Strauzer, CJS Securities]

Great. And then just -- one final question of me looking at the – your US segment, I know are you focusing still on the kind of low end of the margin range there. Is that largely because of the new work you've just won in the Gulf region, or is it just more just related to absorbing some expenses as you've ramped contracts?

[Bruce Caswell, President & Chief Executive Officer]

Yes, I can take that. It's not necessarily related to the new win, Q1 came in at 5%, which is right in the middle of that range, it did have a small benefit from a contractual change, which brought it a little bit higher than the full year estimate. We're still targeting, as you said, the low end of that 3% to 7% range. But I'll say, again, that we're not satisfied at the low end of that range. And we're working hard. And we're committed to improving the margin in the segment.

The segment was very volatile during the COVID period. And so it does seem to have stabilized, which is great albeit in the low single digit margin. So now we're focused on improving that margin up to the mid single digits and then high single digit.

[Charlie Strauzer, CJS Securities]

Great, Thank you very much.

[Bruce Caswell, President & Chief Executive Officer]

Thanks, Charlie.

[Jessica Batt]

At this time, we have no further questions. Operator, back to you.

[Operator]

Thank you. This concludes today's teleconference. You may disconnect your lines this time. We thank you for your participation.